2024-511832-29-00招募中2 期
A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
Universitaet Muenster16 个研究点 分布在 2 个国家目标入组 190 人开始时间: 2024年9月20日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 190
- 试验地点
- 16
- 主要终点
- Progression-free survival (PFS). This endpoint is defined as time interval from randomization until BCR, metastases, or death from any cause, whichever occurs first.
研究概览
简要总结
To determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form (ICF)
- •Ability to swallow study medication tablets
- •In case of apalutamide treatment: Agrees to use a condom and another highly effective method of birth control if he is having sex with a woman of childbearing potential or to use a condom if he is having sex with a woman who is pregnant
- •Men ≥ 18 years of age
- •Patients with histologically confirmed adenocarcinoma of the prostate after radical prostatectomy
- •Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- •Exclusion of metastatic disease by CT-scan of abdomen (MRI of abdomen is possible) and bone scan prior to study inclusion. A PSMA PET-CT/MRI is possible. In this case it has to be done with a diagnostic CT/MRI with contrast media and not with a low dose CT-scan only. In case PSMA-PET imaging has been done, a bone scan can be omitted. CT/MRI, and bone-scan imaging or PSMA PET-CT/MRI administered ≤12 weeks before RPE may be used for screening
- •Patients after RPE must meet the d'Amico criteria for high risk of disease recurrence (T-stage and Gleason-score determined after radical prostatectomy) i.e. 1 of the following after RPE: 1) Gleason score ≥8, any T-stage, any iPSA or 2) Gleason score 6 or 7, any iPSA and ≥pT3 or 3) iPSA >20 ng/ml, any Gleason score, any T-stage.
- •Patients have to have recovered from radical prostatectomy within eight weeks to be able to take part in the study
- •PSA must have declined below 0.2 ng/ml prior to randomization
- •Adequate hematologic, hepatic, and renal function: • Hematologic i) Haemoglobin ≥ 9.0 g/dL independent of transfusions ii) Neutrophils ≥ 1.5 Ths./μL • Hepatic i) Total Bilirubin =< 1.5X upper limit of normal (ULN) [except for subjects with documented Gilbert's disease in which case total bilirubin not to exceed 10X ULN] ii) Alanine (ALT) and aspartate (AST) aminotransferase =< 2.5X ULN • Renal: i) Serum creatinine <1.5X ULN or calculated creatinine clearance ≥ 50 mL/min ii) Serum potassium ≥ 3.5 mM iii) Serum albumin ≥ 3.0 g/dL
排除标准
- •Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone q.d.
- •Any lymph node or distant metastasis
- •History of seizures or condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness ≤1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).
- •Current or prior treatment with anti-epileptic medications for the treatment of seizures
- •Management of cardiovascular risk factors, such as hypertension, diabetes or dyslipidaemia should be optimised as per standard of care before treatment with apalutamide will be initiated 13.
- •Uncontrolled hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. For patients with relevant comorbidities (e.g. diabetes) systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg). Patients with a history of hypertension are allowed provided that blood pressure is controlled by anti-hypertensive treatment 13.
- •Patients with uncontrolled diabetes defined as HbA1c ≥7.5% 13.
- •Patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl. For patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl and SCORE-value of 1-5%: In case of a SCORE-value of <1% a LDL cholesterol level of up to 115 mg/dl is acceptable. In case of increased LDL cholesterol above these values a statin-therapy can be initiated and a rescreening within 4 weeks is possible 13.
- •Cardiovascular risk assessment via an appropriate score (e.g. the SCORE-Chart for the European high/low risk score from the European Society of Cardiology) and ≥ borderline risk i.e. 10% of developing cardiovascular events within 10 years without prior cardiovascular disease
- •Active or symptomatic viral hepatitis or chronic liver disease or HIV
- •History of pituitary or adrenal dysfunction
- •Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of <50% at baseline, or clinically relevant pelvic lymphocele after radical prostatectomy as evaluated by clinical examination and/or pelvic ultrasound (if a risk is present, patients may be allowed to be enrolled after adaptive risk management).
- •Any condition that requires treatment with digoxin, digitoxin, and other digitalis drugs
- •Long QT Syndrome
- •Atrial Fibrillation, or other cardiac arrhythmia requiring therapy
- •Prior cytotoxic chemotherapy or biologic therapy for the treatment of prostate cancer
- •Other malignancy with a ≥30% probability of recurrence within 24 months, except non-melanoma skin cancer
- •Any condition, which, in the opinion of the investigator, would preclude participation in this trial.
- •Gastrointestinal conditions affecting absorption
- •Hypersensitivity to the active substance, or to any of the excipients of the study medication
- •Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, to give informed consent or to comply with the study protocol.
- •Participation in another interventional clinical trial during this trial or within 4 weeks before entry into this trial. There may be exceptions at the discretion of the (coordinating) investigator.
- •Prior or current treatment of prostate cancer with apalutamide, enzalutamide, darolutamide, or other investigational agents targeting the androgen receptor
- •Prior therapy with Sipuleucel-T or other vaccination or immunogenic therapy for the treatment of prostate cancer
- •Prior treatment with abiraterone acetate or other androgen synthesis inhibitors (e. g. ketoconazole, TAK700, TOK001)
- •Use of 5-α reductase inhibitors (eg, dutasteride, finasteride) ≤4 weeks prior to randomization
- •Prior surgical castration or medical castration using LHRH-Agonists or GnRH-Antagonists
- •Prior or current radiation or radionuclide (including radium-223 dichloride) therapy for treatment of prostate cancer (adjuvant radiation of the prostate bed without involvement of the regional lymph node template as by standard of care in case of positive surgical margins (R1) is allowed)
- •Prior or current systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1
结局指标
主要结局
Progression-free survival (PFS). This endpoint is defined as time interval from randomization until BCR, metastases, or death from any cause, whichever occurs first.
Progression-free survival (PFS). This endpoint is defined as time interval from randomization until BCR, metastases, or death from any cause, whichever occurs first.
次要结局
未报告次要终点
研究者
Klinik für Urologie und Kinderurologie am UKM Münster
Scientific
Universitaet Muenster
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of theOral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ITIRX THERAPEUTICS, INC.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 19.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ESIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-HUIRX Therapeutics, Inc.200
进行中（未招募）
1 期
Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of PembrolizumabThis trial investigates whether neoadjuvant radiotherapy combined with pembrolizumab followed by surgical resection and adjuvant pembrolizumab improves disease-free survival for patients with high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3) compared to radiotherapy alone followed by surgical resectionMedDRA version: 20.0Level: PTClassification code 10024629Term: Liposarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001360-39-ITSARC110
已完成
2 期
A phase II study to evaluate the effect of adjuvant chemotherapy using hepatic arterial infusion chemotherapy of 5-fluorouracil plus systemic chemotherapy of gemcitabine after resection of pancreatic cancerresectable pancreatic cancerJPRN-UMIN000000549ara Medical University25